Literature DB >> 24345704

Supplemental oxygen reverses hypoxia-induced smooth muscle cell proliferation by modulating HIF-alpha and VEGF levels in a rabbit arteriovenous fistula model.

Jing Wan1, Charu Lata2, Ashley Santilli2, Derrick Green2, Sabita Roy2, Steven Santilli3.   

Abstract

BACKGROUND: Numerous mechanisms for the formation of intimal hyperplasia have been proposed but none have been proven or accepted. Our research focuses on the potential role of hypoxia-inducible factors (HIFs), vascular endothelial growth factor (VEGF), and platelet-derived growth factors as well as the extracellular signal-regulated kinase (ERK), phosphatidylinositide 3-kinase /protein Kinase B (PI3-K/AKT) pathway in hypoxia-mediated intimal hyperplasia processes. We hypothesize that HIF and VEGF will be downregulated with supplemental oxygen in our arteriovenous fistula rabbit model.
METHODS: Rabbits were randomized into different experimental groups with varying oxygen exposure (21% O2 or 30% O2) and receipt of surgery (surgery with fistula formation, no surgery, or sham operation with skin incision only). Plasma samples were collected at designated intervals in which cytokines and smooth muscle cell proliferation were measured. In addition, cell specimens were exposed to hyperoxic, normoxic, and hypoxic environments with cytokines measured at various time points.
RESULTS: Placement of an arteriovenous fistula resulted in hypoxia-induced HIF stabilization with a concurrent increase in VEGF levels. There was a 4.2-fold induction in HIF-1α levels in animals that were placed in normal air after surgery when compared with animals that were exposed to hyperoxic air. Also, VEGF level significantly increased after surgery in the normoxic group, reaching a maximum of 959 pg/mL. Plasma VEGF levels in the surgery and supplemental oxygen group were significantly lower than the normoxic surgery group with almost a 45% reduction in plasma VEGF levels (524 pg/mL). Activation of VEGF receptors on smooth muscle cells through ERK1 and AKT pathways resulted in significant smooth muscle cell proliferation and migration. These effects are dramatically reduced in animals that are exposed to a hyperoxic environment of 30% oxygen.
CONCLUSIONS: Our results suggest that short-term administration of supplemental oxygen inhibits HIFs and VEGF signaling to reduce smooth muscle proliferation in the local blood vessel. These results provide strong support for the therapeutic use of supplemental oxygen after arterial surgery to reduce intimal hyperplasia. These findings also provide a nidus for future clinical trials to determine whether this is clinically applicable in humans.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24345704      PMCID: PMC3968233          DOI: 10.1016/j.avsg.2013.10.007

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  26 in total

1.  Local infusion of heparin reduces anastomotic neointimal hyperplasia in aortoiliac expanded polytetrafluoroethylene bypass grafts in baboons.

Authors:  C Chen; A B Lumsden; S R Hanson
Journal:  J Vasc Surg       Date:  2000-02       Impact factor: 4.268

2.  III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000.

Authors: 
Journal:  Am J Kidney Dis       Date:  2001-01       Impact factor: 8.860

3.  Vascular access for hemodialysis.

Authors:  S J Schwab; J T Harrington; A Singh; R Roher; S A Shohaib; R D Perrone; K Meyer; D Beasley
Journal:  Kidney Int       Date:  1999-05       Impact factor: 10.612

4.  Effect of ionizing radiation on thymidine uptake, differentiation, and VEGFR2 receptor expression in endothelial cells: the role of VEGF(165).

Authors:  P Kermani; G Leclerc; R Martel; J Fareh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-05-01       Impact factor: 7.038

Review 5.  Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia--a review.

Authors:  A W Clowes; M A Reidy
Journal:  J Vasc Surg       Date:  1991-06       Impact factor: 4.268

Review 6.  Pathobiology of intimal hyperplasia.

Authors:  M G Davies; P O Hagen
Journal:  Br J Surg       Date:  1994-09       Impact factor: 6.939

7.  Sites of stenosis in AV fistulae for haemodialysis access.

Authors:  S Sivanesan; T V How; A Bakran
Journal:  Nephrol Dial Transplant       Date:  1999-01       Impact factor: 5.992

8.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.

Authors:  E Tischer; R Mitchell; T Hartman; M Silva; D Gospodarowicz; J C Fiddes; J A Abraham
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

9.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

Authors:  K A Houck; N Ferrara; J Winer; G Cachianes; B Li; D W Leung
Journal:  Mol Endocrinol       Date:  1991-12

10.  Suppression of intimal hyperplasia in experimental vein grafts by oral l-arginine supplementation and single ex vivo immersion in deferoxamine manganese.

Authors:  M G Davis; H Dalen; A M Austerheim; T F Gulbrandsen; E Svendsen; P O Hagen
Journal:  J Vasc Surg       Date:  1996-03       Impact factor: 4.268

View more
  16 in total

Review 1.  The Biology of Hemodialysis Vascular Access Failure.

Authors:  Akshaar Brahmbhatt; Sanjay Misra
Journal:  Semin Intervent Radiol       Date:  2016-03       Impact factor: 1.513

2.  Systemic Profile of Cytokines in Arteriovenous Fistula Patients and Their Associations with Maturation Failure.

Authors:  Laisel Martinez; Mikael Perla; Marwan Tabbara; Juan C Duque; Miguel G Rojas; Nieves Santos Falcon; Simone Pereira-Simon; Loay H Salman; Roberto I Vazquez-Padron
Journal:  Kidney360       Date:  2022-01-13

Review 3.  Role of smooth muscle cells in coronary artery bypass grafting failure.

Authors:  Kerry Wadey; Joshua Lopes; Michelle Bendeck; Sarah George
Journal:  Cardiovasc Res       Date:  2018-03-15       Impact factor: 10.787

4.  Evaluation of Venous Stenosis Angioplasty in a Murine Arteriovenous Fistula Model.

Authors:  Chuanqi Cai; Binxia Yang; Sreenivasulu Kilari; Yiqing Li; Chenglei Zhao; Amit Sharma; Sanjay Misra
Journal:  J Vasc Interv Radiol       Date:  2019-03-20       Impact factor: 3.464

5.  Tongxinluo inhibits cyclooxygenase-2, inducible nitric oxide synthase, hypoxia-inducible factor-2α/vascular endothelial growth factor to antagonize injury in hypoxia-stimulated cardiac microvascular endothelial cells.

Authors:  Yan-Ning Li; Xiu-Juan Wang; Bin Li; Kun Liu; Jin-Sheng Qi; Bing-Hui Liu; Ye Tian
Journal:  Chin Med J (Engl)       Date:  2015-04-20       Impact factor: 2.628

6.  Promoting Vasa Vasorum Neovascularization of Vein Grafts Extenuates Hypoxia of the Wall and Its Subsequent Influence on Intimal Hyperplasia.

Authors:  Rong-Jiang Zou; Zheng-Hua Wang; Chen-Xi Wang; Song Xue
Journal:  Chin Med J (Engl)       Date:  2017-06-05       Impact factor: 2.628

7.  MMP-9 Deletion Attenuates Arteriovenous Fistula Neointima through Reduced Perioperative Vascular Inflammation.

Authors:  Yu-Chung Shih; Po-Yuan Chen; Tai-Ming Ko; Po-Hsun Huang; Hsu Ma; Der-Cherng Tarng
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

8.  Hypoxia Differentially Regulates Arterial and Venous Smooth Muscle Cell Migration.

Authors:  Alice Chanakira; Devika Kir; Roderick A Barke; Steve M Santilli; Sundaram Ramakrishnan; Sabita Roy
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

Review 9.  The molecular mechanisms of hemodialysis vascular access failure.

Authors:  Akshaar Brahmbhatt; Andrea Remuzzi; Marco Franzoni; Sanjay Misra
Journal:  Kidney Int       Date:  2016-02       Impact factor: 10.612

10.  Blockade of vascular endothelial growth factor receptor 2 inhibits intraplaque haemorrhage by normalization of plaque neovessels.

Authors:  M R de Vries; L Parma; H A B Peters; A Schepers; J F Hamming; J W Jukema; M J T H Goumans; L Guo; A V Finn; R Virmani; C K Ozaki; P H A Quax
Journal:  J Intern Med       Date:  2018-09-07       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.